IL6 and metabolic syndrome: Network pharmacology and joint pathway enrichment were further used to cross-validate target prediction with metabolite-level readouts and to prioritize gut-microbiota-metabolism-phenotype links.<h4>Results</h4>DSG attenuated ST-segment elevation, reduced myocardial histopathological injury, mitigated dyslipidemia, and lowered systemic inflammatory mediators, including TNF-α and IL-6.